Manidipine in hypertensive patients with metabolic syndrome: The MARIMBA study

Expert Review of Cardiovascular Therapy

Volumn 7, Issue 7, 2009, Pages 863-869

  Martínez Martín, Francisco Javier ^a  

^a HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

Author keywords

Adiponectin; Amlodipine; C reactive protein; Hypertension; Insulin sensitivity; Manidipine; Metabolic syndrome; Microalbuminuria; TNF

Indexed keywords

ADIPONECTIN; AMLODIPINE; C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANIDIPINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE;

ALBUMINURIA; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; ADULT; AGED; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349337405     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.53     Document Type: Article

References (31)

1. Schillaci G, Pirro M, Vaudo G et al. Prognostic value of the metabolic syndrome in essential hypertension. J. Am. Coll. Cardiol. 43(10), 1817-1822 (2004).
2. Barrios V, Escobar C, Calderón A et al. Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis. J. Cardiometab. Syndr. 2(1), 9-15 (2007).
3. Liu SJ, Guo ZR, Hu XS et al. Risks for Type-2 diabetes associated with the metabolic syndrome and the interaction between impaired fasting glucose and other components of metabolic syndrome: the study from Jiangsu, China of 5 years follow-up. Diabetes Res. Clin. Pract. 81(1), 117-123 (2008). •Shows the high predictive value for the presence of hypertension in patients with metabolic syndrome with respect to development of Type 2 diabetes.
4. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201-207 (2007). ••Of the many reviews on the issue of antihypertensive drugs and new-onset Type 2 diabetes, this one is particularly comprehensive and authoritative.
5. European Society of Hypertension- European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 21(6), 1011-1053 (2003).
6. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J. Hypertens. 25(6), 1105-1187 (2007).
7. Iimura O, Shimamoto K, Masuda A et al. Effects of a calcium channel blocker, manidipine, on insulin sensitivity in essential hypertensives. J. Diabetes Complicat. 9(4), 215-219 (1995).
8. Suzuki S, Ohtomo M, Satoh Y et al. Effect of manidipine and delapril on insulin sensitivity in Type 2 diabetic patients with essential hypertension. Diabetes Res. Clin. Pract. 33(1), 43-51 (1996). (Pubitemid 26275953)
9. Fogari R, Derosa G, Zoppi A et al. Effect of delapril/manidipine vs olmesartan/hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients. Intern. Med. 47(5), 361-366 (2008). ••Shows the most marked improvement of insulin sensitivity elicited by antihypertensive drugs (delapril plus manidipine) in the available literature.
10. Koh KK, Quon MJ, Han SH et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int. J. Cardiol. DOI: 10.1016/j.ijcard.2008.11.017 (2008) (Epub ahead of print).
11. Bakris G, Molitch M, Hewkin A et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 29(12), 2592-2597 (2006). ••Proves that a presently recommended treatment (angiotensin-renin system blocker plus low-dose thiazide diuretic) can markedly increase the risk of developing Type 2 diabetes in hypertensive patients with metabolic syndrome.
12. Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc. Diabetol. 6, 12 (2007).
13. Heidemann C, Sun Q, van Dam RM et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for Type 2 diabetes in women. Ann. Intern. Med. 149(5), 307-316 (2008). ••Demonstrates the extremely high predictive power of low adiponectin levels with respect to the development of Type 2 diabetes.
14. Sjöholm A, Nyström T. Inflammation and the etiology of Type 2 diabetes. Diabetes Metab. Res. Rev. 22(1), 4-10 (2006).
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation 106(25), 3143-3421 (2002).
16. WHO/International Diabetes Consultation. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycaemia. WHO, Geneva, Switzerland (2006).
17. Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1(2), 113-119 (1992).
18. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care 27(6), 1487-1495 (2004).
19. Redon J, Cifkova R, Laurent S et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J. Hypertens. 26(10), 1891-1900 (2008).
20. Martinez-Martin FJ, Saiz-Satjes M. Add-on Manidipine versus Amlodipine in Diabetic Patients with Hypertension and Microalbuminuria: the AMANDHA study. Expert Rev. Cardiovasc. Ther. 6(10), 1347-1355 (2008). •Shows the remarkable antiproteinuric properties of manidipine, which are independent of its antihypertensive effect.
21. 2+ channel subtypes and pharmacology in the kidney. Circ. Res. 100(3), 342-353 (2007).
22. Ueshiba H, Miyachi Y. Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. Intern. Med. 43(7), 561-565 (2004). (Pubitemid 39206693)
23. Luque Otero M, Martell Clarós N; Study Investigators Group. Mandipine versus enalapril monotherapy in patients with hypertension and Type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin. Ther. 27(2), 166-173 (2005).
24. Nakami T. PPAR-g activation by manidipine mediates enhanced adiponectin production and insulin sensitivity. J. Hypertens. 24(Suppl. 6), S161 (2006).
25. Oshimura H, Nakami T, Javier M. Manidipine has a marked nonhaemodynamic nephroprotective action; partly dependent on PPAR-g activation, and synergistic with angiotensin receptor blockade. J. Hypertens. 25(Suppl. 2), S8 (2007).
26. Nakami T. Manidipine prevents hepatic C-reactive protein production and reactive oxygen species generation by downregulation of the AGE receptor expression, dependent on PPR-gamma activation. J. Hypertens. 25(Suppl. 2), S119-S120 (2007).
27. Boyle PJ. What are the effects of peroxisome proliferator-activated receptor agonists on adiponectin, tumor necrosis factor-alpha, and other cytokines in insulin resistance? Clin. Cardiol. 27(7 Suppl. 4), IV11-IV16 (2004).
28. Mohler ER 3rd, Sorensen LC, Ghali JK et al. Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. J. Am. Coll. Cardiol. 30(1), 35-41 (1997).
29. Whitehead JP, Richards AA, Hickman IJ, MacDonald GA, Prins JB. Adiponectin a key adipokine in the metabolic syndrome. Diabetes Obes. Metab. 8 (3), 264-280 (2006). •Clear and comprehensive review of the role (or lack thereof) of adiponectin in the metabolic syndrome.
30. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347(20), 1557-1565 (2002). •Proves that C-reactive protein is at least as good a predictor of cardiovascular events as low-density lipoprotein cholesterol.
31. Smith DH, Neutel JM, Lacourcière Y, Kempthorne-Rawson J. Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements. J. Hypertens. 21(7), 1291-1298 (2003). (Pubitemid 36930235)